Listed

Senti Biosciences Holdings, Inc.

SNTINasdaqCIK 1854270HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$17.0kRevenue, Q2 FY2026, three months to 2026-06-30$17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 14, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$17.0kRevenue, Q2 FY2026, three months to 2026-06-30$17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figureSign changed from a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−85229.4%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$14.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Revenue: $17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figureNo year-earlier figure to compare
  • Net margin−75000.0%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$12.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Revenue: $17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figureNo year-earlier figure to compare
  • Diluted EPS−$0.41Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure+26.8% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$17.0kOperating margin −85229.4%
Diluted EPS−$0.41, Q2 FY2026
Free cash flow−$6.9m, Q4 FY2025
Senti Biosciences Holdings, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)0.0Revenue, Q1 FY2026, three months to 2026-03-31$16.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)not reported (Revenue not reported)(28850.0%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$4.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Revenue: $16.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(85229.4%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$14.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Revenue: $17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Net margin%not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)not reported (Revenue not reported)(26381.3%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Revenue: $16.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(75000.0%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$12.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Revenue: $17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Diluted EPS$ per share(6.31)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$6.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figurenot reported (Diluted EPS not reported)(1.41)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(0.56)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure(0.69)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figurenot reported (Diluted EPS not reported)(0.14)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(0.41)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Free cash flow$m(7.9)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$7.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001628280-25-052125. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001628280-25-052125. Derived: 9-month figure less the 6-month figure.Report this figure(13.5)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$13.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Capital expenditure: $11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure(14.1)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$14.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure(13.3)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001628280-26-057110. Derived: 6-month figure less the 3-month figure.Capital expenditure: $196.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001628280-26-057110. Derived: 6-month figure less the 3-month figure.Report this figure(9.4)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$9.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001628280-25-052125. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001628280-25-052125. Derived: 9-month figure less the 6-month figure.Report this figure(6.9)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$6.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$22.0kOperating margin −312631.8%
Diluted EPS−$2.73, FY2025
Free cash flow−$43.6m, FY2025
Senti Biosciences Holdings, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m2.3Revenue, FY2021, twelve months to 2021-12-31$2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-22, accession 0001854270-23-000033.Report this figure3.3Revenue, FY2022, twelve months to 2022-12-31$3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-21, accession 0001854270-24-000029.Report this figure2.0Revenue, FY2023, twelve months to 2023-12-31$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figure0.0Revenue, FY2024, twelve months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure0.0Revenue, FY2025, twelve months to 2025-12-31$22.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(1765.4%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$40.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-22, accession 0001854270-23-000033.Revenue: $2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-22, accession 0001854270-23-000033.Report this figure(1889.3%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$62.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-21, accession 0001854270-24-000029.Revenue: $3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-21, accession 0001854270-24-000029.Report this figure(4687.9%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$92.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-20, accession 0001854270-25-000042.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figurenot reported (Revenue of zero not reported)(312631.8%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$68.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001628280-26-021580.Revenue: $22.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure
Net margin%(2414.6%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$55.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-22, accession 0001854270-23-000033.Revenue: $2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-22, accession 0001854270-23-000033.Report this figure(1771.5%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$58.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-21, accession 0001854270-24-000029.Revenue: $3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-21, accession 0001854270-24-000029.Report this figure(3592.4%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$71.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-20, accession 0001854270-25-000042.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figurenot reported (Revenue of zero not reported)(279263.6%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$61.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-27, accession 0001628280-26-021580.Revenue: $22.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure
Diluted EPS$ per share(19.00)Diluted EPS, FY2021, twelve months to 2021-12-31−$19.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-22, accession 0001854270-23-000033.Report this figure(2.23)Diluted EPS, FY2022, twelve months to 2022-12-31−$2.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-21, accession 0001854270-24-000029.Report this figure(16.01)Diluted EPS, FY2023, twelve months to 2023-12-31−$16.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figure(12.03)Diluted EPS, FY2024, twelve months to 2024-12-31−$12.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure(2.73)Diluted EPS, FY2025, twelve months to 2025-12-31−$2.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure
Free cash flow$m(40.2)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$34.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-22, accession 0001854270-23-000033.Capital expenditure: $5.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-22, accession 0001854270-23-000033.Report this figure(76.3)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$34.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-21, accession 0001854270-24-000029.Capital expenditure: $41.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-21, accession 0001854270-24-000029.Report this figure(64.4)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$52.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-20, accession 0001854270-25-000042.Capital expenditure: $12.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figure(41.4)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$41.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001628280-26-021580.Capital expenditure: $26.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure(43.6)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$43.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001628280-26-021580.Capital expenditure: $196.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Senti Biosciences Holdings, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Nantahala Capital Management, LLC2026-06-30$976.8k888,000New+888,000
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$591.3k537,504New+537,504
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$205.8k187,065New+187,065
CITADEL ADVISORS LLC2026-06-30$117.8k107,100New+107,100
VANGUARD FIDUCIARY TRUST CO2026-06-30$100.3k91,193New+91,193
JANE STREET GROUP, LLC2026-06-30$57.8k52,530New+52,530
Menlo Ventures Management, L.P.2026-06-30$39.3k35,737New+35,737
NORTHERN TRUST CORP2026-06-30$35.4k32,154New+32,154
XTX Topco Ltd2026-06-30$26.0k23,610New+23,610
UBS Group AG2026-06-30$15.9k14,432New+14,432

Recent filings

All 361 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Senti Biosciences Holdings, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2616:17 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0001140361-26-040772
2026-10-1516:02 ET8-K5.07 Shareholder vote results0001628280-26-065992
2026-10-1316:01 ET8-K8.01 Other events0001628280-26-065685
2026-09-2416:03 ET8-K5.02 Departure or appointment of officers or directors0001628280-26-063369
2026-09-1117:00 ETSCHEDULE 13D/AOwnership report, active investor, amended0000902664-26-003795
2026-09-0406:01 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001628280-26-060600
2026-09-0216:29 ET8-K1.01 Entry into a material agreement; 3.01 Delisting notice0001628280-26-060124
2026-08-2016:25 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation0001628280-26-058258
2026-08-1416:10 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-057110
2026-07-1613:56 ETSCHEDULE 13D/AOwnership report, active investor, amended0000902664-26-003126

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 27, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1854270
Tickers
SNTI
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
<br>Emerging growth company
Former names
Senti Biosciences, Inc. (to 2026-05-08); Senti Biosciences, Inc.\ (to 2022-06-28); Dynamics Special Purpose Corp. (to 2022-06-13)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:38 ET. Listed shows no prices and gives no investment advice.